Efficacy, safety and tolerability of a delamanid-containing regimen for 24 weeks in the treatment of multidrug-resistant-tuberculosis and extensively drug resistant (XDR-TB)
Latest Information Update: 19 Apr 2021
Price :
$35 *
At a glance
- Drugs Bedaquiline (Primary) ; Delamanid (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; Therapeutic Use
- 10 Apr 2021 Results published in the Clinical Infectious Diseases
- 07 Nov 2017 New trial record
- 23 Oct 2017 Interim results (n=32) published in the Journal of Antimicrobial Chemotherapy.